Advanced search
Publication Cover
Current Medical Research and Opinion Volume 35, 2019 - Issue 6
Submit an article Journal homepage
4,466
Views
48
CrossRef citations to date
0
Altmetric
Immunology

Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation

Jingbo YuIncyte Corporation, US Medical Affairs, Wilmington, DE, USA; Correspondence[email protected]
,
Shreekant ParasuramanIncyte Corporation, US Medical Affairs, Wilmington, DE, USA;
,
Anshul ShahEvidera Inc., Modeling and Simulation, Waltham, MA, USA;
&
Daniel WeisdorfUniversity of Minnesota, Department of Medicine, Division of Hematology, Oncology and Transplantation, Minneapolis, MN, USA
Pages 983-988 | Received 08 Oct 2018, Accepted 24 Oct 2018, Published online: 20 Dec 2018

References

  • D’Souza A, Fretham C. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides [Internet] 2017. Center for International Blood and Marrow Transplant Research, 2017 [cited 2018 Jul 18]. Available from: http://www.cibmtr.org.
  • Singh AK, McGuirk JP. Allogeneic stem cell transplantation: a historical and scientific overview. Cancer Res. 2016;76:6445–6451.
  • Holtan SG, DeFor TE, Lazaryan A, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333–1338.
  • Stranges E, Russo CA, Friedman B. HCUP Statistical Brief #82. Procedures with the most rapidly increasing hospital costs, 2004–2007 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality, 2009 [cited 2017 Oct 12]. Available from: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb82.pdf.
  • Majhail NS, Mau LW, Denzen EM, Arneson TJ. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transplant. 2013;48:294–300.
  • Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550–1561.
  • Gratwohl A, Brand R, Frassoni F, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 2005;36:757–769.
  • Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296–307.
  • Khoury HJ, Wang T, Hemmer MT, et al. Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica. 2017;102:958–966.
  • United States Department of Health and Human Services. Code of Federal Regulations: Title 45 Part 46- Protection of Human Subjects [Internet]. 2009 [cited 2018 Jun 28]. Available from: https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cf r-46/index.html.
  • Healthcare Cost and Utilization Project. Chronic condition indicator [Internet]. Rockville, MD: Agency for Healthcare Research and Quality, 2016 [cited 2017 Sep 20]. Available from: www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic.jsp.
  • Sundaramurthi T, Wehrlen L, Friedman E, et al. Hematopoietic stem cell transplantation recipient and caregiver factors affecting length of stay and readmission. Oncol Nurs Forum. 2017;44:571–579.
  • Lee SJ, Klar N, Weeks JC, Antin JH. Predicting costs of stem-cell transplantation. J Clin Oncol. 2000;18:64–71.
  • Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant. 2009;15:564–573.
  • Bennett C, Waters T, Stinson T, et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;24:555–560.
  • Center for International Blood & Marrow Transplant Research (CIBMTR). HCT trends and survival data [Internet]. 2015 [cited 2017 Oct 6]. Available from: https://www.cibmtr.org/referencecenter/slidesreports/summaryslides/Pages/index.aspx.
  • Grubb WW, Huse S, Alam N, et al. Economic burden of acute graft-versus-host disease (GvHD) following allogeneic hematopoietic cell transplant (HCT) for hematologic malignancies. Blood. 2016;128:1187.
  • Svahn BM, Remberger M, Alvin O, et al. Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. Bone Marrow Transplant. 2012;47:706–715.
  • Gamper CJ, Takemoto CM, Chen AR, et al. High-dose cyclophosphamide is effective therapy for pediatric severe aplastic anemia. J Pediatr Hematol Oncol. 2016;38:627–635.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.